<DOC>
	<DOCNO>NCT01352793</DOCNO>
	<brief_summary>A multicenter phase 3 safety trial 5,700 subject assign 2:1 ratio receive 120 Î¼g rLP2086 vaccine 0 , 2 , 6 month schedule control . The control group receive HAVRIX vaccine month 0 6 saline month 2 . All subject follow 6 month last vaccination assess safety tolerability .</brief_summary>
	<brief_title>A Global Phase 3 Safety Study 120 mcg rLP2086 Vaccine Adolescents Young Adults Aged 10 25 Years</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy subject age 10 25 year . Previous vaccination Hepatitis A virus vaccine Previous vaccination investigational meningococcal B vaccine History cultureproven N. meningitidis serogroup B disease Any neuroinflammatory autoimmune condition Any immune defect would prevent effective response study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>phase 3 safety study</keyword>
	<keyword>5700 healthy subject</keyword>
	<keyword>3 vaccine dos month 0</keyword>
	<keyword>2</keyword>
	<keyword>6</keyword>
	<keyword>control HAV/saline/HAV</keyword>
</DOC>